3. Liu Q, Ding L, Qiu X, Meng F. Updated evaluation of endoscopic submucosal dissection versus surgery for early gastric cancer: a systematic review and meta-analysis. Int J Surg 2020;73:28–41.
4. Abdelfatah MM, Barakat M, Ahmad D, et al. Long-term outcomes of endoscopic submucosal dissection versus surgery in early gastric cancer: a systematic review and meta-analysis. Eur J Gastroenterol Hepatol 2019;31:418–424.
6. Ford AC, Yuan Y, Moayyedi P.
Helicobacter pylori eradication therapy to prevent gastric cancer: systematic review and meta- analysis. Gut 2020;69:2113–2121.
7. Pimentel-Nunes P, Libânio D, Marcos-Pinto R, et al. Management of epithelial precancerous conditions and lesions in the stomach (MAPS II): European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter and Microbiota Study Group (EHMSG), European Society of Pathology (ESP), and Sociedade Portuguesa de Endoscopia Digestiva (SPED) guideline update 2019. Endoscopy 2019;51:365–388.
9. den Hoed CM, Holster IL, Capelle LG, et al. Follow-up of premalignant lesions in patients at risk for progression to gastric cancer. Endoscopy 2013;45:249–256.
10. de Vries AC, van Grieken NC, Looman CW, et al. Gastric cancer risk in patients with premalignant gastric lesions: a nationwide cohort study in the Netherlands. Gastroenterology 2008;134:945–952.
11. Sterne JAC, Higgins JPT, Reeves BC, on behalf of the development group for ACROBATNRSI. A Cochrane Risk Of Bias Assessment Tool: for Non-RandomizedStudies of Interventions (ACROBATNRSI), Version 1.0.0 24. September. 2014. Available from
http://www.riskofbias.info
. accessed 7 October 2022.
12. Kimura K, Takemoto T. An endoscopic recognition of the atrophic border and its significance in chronic gastritis. Endoscopy 1969;1:87–97.
13. Dixon MF, Genta RM, Yardley JH, Correa P. Classification and grading of gastritis. The updated Sydney System. International Workshop on the Histopathology of Gastritis, Houston 1994. Am J Surg Pathol 1996;20:1161–1181.
14. Noh G, Kim N, Choi Y, et al. Long-term follow up of serum pepsinogens in patients with gastric cancer or dysplasia after
Helicobacter pylori eradication. J Gastroenterol Hepatol 2020;35:1540–1548.
15. Yoshida T, Kato J, Inoue I, et al. Cancer development based on chronic active gastritis and resulting gastric atrophy as assessed by serum levels of pepsinogen and
Helicobacter pylori antibody titer. Int J Cancer 2014;134:1445–1457.
16. Ohkusa T, Miwa H, Nomura T, et al. Improvement in serum pepsinogens and gastrin in long-term monitoring after eradication of
Helicobacter pylori: comparison with
H. pylori-negative patients. Aliment Pharmacol Ther 2004;20:Suppl 1. 25–32.
17. Stewart LA, Clarke M, Rovers M, et al.; PRISMA-IPD Development Group. Preferred reporting items for systematic review and meta-analyses of individual participant data: the PRISMA-IPD Statement. JAMA 2015;313:1657–1665.
18. Liberati A, Altman DG, Tetzlaff J, et al. The PRISMA statement for reporting systematic reviews and meta-analyses of studies that evaluate health care interventions: explanation and elaboration. Ann Intern Med 2009;151:W65–94.
19. Han JS, Jang JS, Choi SR, et al. A study of metachronous cancer after endoscopic resection of early gastric cancer. Scand J Gastroenterol 2011;46:1099–1104.
20. Han SJ, Kim SG, Lim JH, et al. Long-term effects of
Helicobacter pylori eradication on metachronous gastric cancer development. Gut Liver 2018;12:133–141.
21. Hanaoka N, Uedo N, Shiotani A, et al. Autofluorescence imaging for predicting development of metachronous gastric cancer after
Helicobacter pylori eradication. J Gastroenterol Hepatol 2010;25:1844–1849.
23. Moribata K, Iguchi JK, Nakachi K, et al. Endoscopic features associated with development of metachronous gastric cancer in patients who underwent endoscopic resection followed by
Helicobacter pylori eradication. Dig Endosc 2016;28:434–442.
24. Kato M, Hayashi Y, Nishida T, et al.
Helicobacter pylori eradication prevents secondary gastric cancer in patients with mild-to-moderate atrophic gastritis. J Gastroenterol Hepatol 2021;36:2083–2090.
25. Kim SB, Lee SH, Bae SI, et al. Association between
Helicobacter pylori status and metachronous gastric cancer after endoscopic resection. World J Gastroenterol 2016;22:9794–9802.
26. Maehata Y, Nakamura S, Fujisawa K, et al. Long-term effect of
Helicobacter pylori eradication on the development of metachronous gastric cancer after endoscopic resection of early gastric cancer. Gastrointest Endosc 2012;75:39–46.
27. Oura H, Matsumura T, Kawasaki Y, et al. Long-term use of proton pump inhibitors does not affect ectopic and metachronous recurrence of gastric cancer after endoscopic treatment. Scand J Gastroenterol 2020;55:209–215.
31. Kim EH, Kang H, Park CH, et al. The optimal serum pepsinogen cut-off value for predicting histologically confirmed atrophic gastritis. Dig Liver Dis 2015;47:663–668.
33. Wang X, Lu B, Meng L, Fan Y, Zhang S, Li M. The correlation between histological gastritis staging- ‘OLGA/OLGIM’ and serum pepsinogen test in assessment of gastric atrophy/intestinal metaplasia in China. Scand J Gastroenterol 2017;52:822–827.
35. Jeong JH, Lee SY, Han HS, Kim JH, Sung IK, Park HS. Five autoimmune gastritis patients with positive findings of serum anti-parietal cell antibodies. Korean J Helicobacter Up Gastrointest Res 2021;21:226–234Korean.
36. Shichijo S, Hirata Y, Niikura R, et al. Histologic intestinal metaplasia and endoscopic atrophy are predictors of gastric cancer development after
Helicobacter pylori eradication. Gastrointest Endosc 2016;84:618–624.
37. Choi IJ, Kook MC, Kim YI, et al.
Helicobacter pylori therapy for the prevention of metachronous gastric cancer. N Engl J Med 2018;378:1085–1095.
38. Li WQ, Zhang JY, Ma JL, et al. Effects of
Helicobacter pylori treatment and vitamin and garlic supplementation on gastric cancer incidence and mortality: follow-up of a randomized intervention trial. BMJ 2019;366:l5016.
39. Yan L, Chen Y, Chen F, et al. Effect of
Helicobacter pylori eradication on gastric cancer prevention: updated report from a randomized controlled trial with 26.5 years of follow-up. Gastroenterology 2022;163:154–162e3.